Development of immunocompetent models for primary and metastatic ER + breast cancer
Animal Models and Experimental Medicine · 2026-05 · 9 (5) · 866-878
DOI: 10.1002/ame2.70210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, online erschienen am 12.05.2026. Verfasst von Devon M Bull und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Receptors, Estrogen, Breast Neoplasms, Disease Models, Animal, Mammary Neoplasms, Experimental. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otago Medical Research Foundation (New Zealand), Cancer Research Trust (New Zealand).
Abstract (Originalsprache)
Background
The development of effective therapeutic strategies for late‐stage estrogen receptor‐positive breast cancer (ER+) is limited by the scarcity of biologically relevant models. More recently, immunotherapies emerged as promising candidates for breast cancer treatment, however, the absence of immunocompetent models of ER+ breast cancer metastasis continues to hinder the assessment of these theraputic interventions.
Methods
To address this, we utilized the 129S6/SvEv mouse strain and syngeneic SSM3 cells in the assessment and development of ER+ metastasis models. As part of this study, the mammary intraductal (MIND) primary tumor model was established in the same background. In addition, a novel luciferase system was evaluated for potential use in metastasis tracking.
Results
Luciferase‐expressing SSM3 cells enabled longitudinal in vivo imaging to track tumor growth. Histological analysis confirmed metastatic spread and tumor origin. Antares2, a novel luciferase reporter, showed high in vitro sensitivity but reduced in vivo performance. The study showed that systemic delivery of SSM3 cells with oestradiol supplementation can support metastatic tumor establishment and that MIND injections led to reliable, invasive tumor growth.
Conclusions
These findings highlight the potential and limitations of the 129S6/SvEv model as a syngeneic, immunocompetent system for studying ER+ breast cancer metastasis. Reporter expression may affect immunogenicity or cell fitness. Further refinement of these models will enable investigation of immune‐modulatory therapies in ER+ metastatic breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Otago, Dunedin, New Zealand.
- Department of Pathology and Biomedical Sciences, University of Otago, Christchurch, New Zealand.
- Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
ORCID-Profile: Devon M Bull
Förderung
- Otago Medical Research Foundation (New Zealand)
- Cancer Research Trust (New Zealand)
Zitieren
APA
Bull, D. M., Hazlett, J., Schulpen, E., Tunnicliffe, S., McLellan, A. D., & Dunbier, A. K. (2026). Development of immunocompetent models for primary and metastatic ER + breast cancer. Animal Models and Experimental Medicine, 9(5), 866-878. https://doi.org/10.1002/ame2.70210
Vancouver
Bull DM, Hazlett J, Schulpen E, Tunnicliffe S, McLellan AD, Dunbier AK. Development of immunocompetent models for primary and metastatic ER + breast cancer. Animal Models and Experimental Medicine. 2026;9(5):866-878. doi:10.1002/ame2.70210
BibTeX
@article{Bull2026,
author = {Bull, Devon M and Hazlett, Jody and Schulpen, Emily and Tunnicliffe, Sophie and McLellan, Alexander D and Dunbier, Anita K},
title = {Development of immunocompetent models for primary and metastatic ER + breast cancer},
journal = {Animal Models and Experimental Medicine},
year = {2026},
volume = {9},
number = {5},
pages = {866--878},
doi = {10.1002/ame2.70210}
}
EUVIMED